BioSante Pharmaceuticals, Inc. Announces Subcontract With The University Of Nebraska-Lincoln

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb. 6, 2006--BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that BioSante has been awarded a subcontract valued at $250,000 for the development of recombinant Factor IX (FIX) formulations for delivery via alternative routes of administration. The subcontract was awarded to BioSante by the University of Nebraska-Lincoln as part of their five year $10M grant entitled "cGMP Recombinant FIX for IV and Oral Hemophilia B Therapy" from the National Institutes of Health (NIH).